CLBT vs SNPS: fair value comparison
Cellebrite DI Ltd. and Synopsys, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Technology, CLBT currently sits closer to the top of our discount ranking.
| CLBT | SNPS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $11.85 | $397.38 |
| 12-month range | $11.85–$18.50 | $388.76–$492.29 |
| Sector rank | #48 of 200 Technology | #53 of 200 Technology |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: CLBT fair value analysis · SNPS fair value analysis